FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized ...
Read moreAd hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized ...
Read moreTOFIDENCE™ complements existing portfolio of immunology biosimilars commercialized by Biogen Cambridge, Mass., June 24, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. ...
Read moreReport highlights latest biosimilar pricing and market share status, including state of the adalimumab marketBiosimilar Deep Dive section illustrates patient ...
Read moreThe anti-diabetic biosimilar has been launched under the brand name Lirafit™, and is indicated for improving glycemic control in adult patients with ...
Read more© 2015 - 2024 LifeCare News - LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283 - Lifecarenews.in.
© 2015 - 2024 LifeCare News - LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283 - Lifecarenews.in.